Overexpression of p53 is found in∼ 50% of human cancers, making it an attractive target
antigen for immunotherapy of cancer. Research in this area has thus far primarily focused on …

Tumorigenesis is frequently associated with mutation and overexpression of p53, which
makes it an attractive target antigen for T cell–mediated immunotherapy of cancer. However …

ABSTRACT p53 was reported to be an attractive immunotherapy target because it is
mutated in approximately half of human cancers, resulting in its inactivation and often …

Abstract p53 mutations are frequently found in human cancers and are often associated with
the overexpression of wild-type (WT) protein or peptide sequences, supporting the notion …

CTLs specific to p53 were previously shown to efficiently eradicate p53-overexpressing
tumor cells in vitro as well as in vivo. In this report, we demonstrate that these CTLs can also …

The tumor suppressor protein p53 is overexpressed in close to 50% of all human
malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic …

Elevated levels of the p53 protein occur in∼ 50% of human malignancies, which makes it an
excellent target for a broad-spectrum T cell immunotherapy of cancer. A major barrier to the …

Approximately 50% of all human malignancies exhibit mutation and aberrant expression of
p53, making this protein an interesting candidate target for immunotherapy of cancer …

Current evidence suggests that the optimal vaccines for cancer should incorporate tumor-
specific cytotoxic as well as helper epitopes. Wild-type sequence (wt) p53 peptides are …

Tumor suppressor p53 is reported to be an attractive immunotherapy target because it is
mutated in approximately half of human cancers, resulting in inactivation and often an …